fda shortage tirzepatide October 3, 2024 - Is compoundedtirzepatideFDA-approved FDA FDA Declares End to Tirzepatide Shortage: What You Need to Know

Compoundedtirzepatidebanned The FDA has officially declared an end to the shortage of tirzepatide injection products. This significant announcement, made on December 19, 2024, marks a turning point after tirzepatide injection products were initially added to the FDA's drug shortage list on December 15, 2022. The resolution of this shortage has had a profound impact on access to important medications, particularly impacting compounding pharmacies and the availability of Mounjaro and Zepbound, which both contain tirzepatide as their active ingredientFDA Releases Declaratory Order Regarding Tirzepatide ....

For healthcare professionals and patients alike, understanding the timeline and implications of this resolution is crucial. The FDA's decision to remove tirzepatide from its drug shortage list signals a return to more standard regulatory practices.GLP-1 Weight-Loss Drugs Off Shortage List Initially, the tirzepatide shortage is officially resolved was signaled with earlier determinations, including one around October 3, 2024, when the FDA determined the tirzepatide shortage was resolved. This was further solidified with a declaratory order on December 19, 2024, confirming that the shortage of tirzepatide injection products is over.

The duration of the shortage, spanning over two years, allowed for certain flexibilities, particularly for compounding pharmacies.2025年1月24日—A. In its Declaratory Statement,FDAexplained that it will abstain from taking action against compound pharmacies so long as they discontinue ... These entities were able to produce tirzepatide products during the shortage period. However, with the FDA removed tirzepatide injection from its shortage list, and reaffirming its decision on December 19, 2024, these flexibilities are ending. The FDA has issued clear directives, with some dates set for companies to cease distribution of compounded forms of tirzepatide2024年12月20日—In October 2024,FDA determined that the tirzepatide shortage was resolvedand removed it from the drug shortage list. However, the Outsourcing .... This move is in line with the FDA's broader efforts to address the complexities surrounding GLP-1 medications and their compounding.The GLP-1 Saga Continues: FDA Ends the Tirzepatide ...

The FDA's role in managing drug shortages, including those for tirzepatide, is multifaceted. Drug shortages can occur for numerous reasons, such as manufacturing and quality problems, delays, and discontinuations. In the case of tirzepatide, its inclusion on the shortage list highlighted a period of limited availability.FDA's Concerns with Unapproved GLP-1 Drugs Used for ... The subsequent resolution signifies that the supply chain has stabilized to a point where the FDA no longer considers it to be in short supply.

It's important to note that the FDA has also been actively monitoring the market for unapproved drugs and illicit marketing practices. In warnings issued on February 6, 2026, the FDA indicated its intent to take action against compounded GLP-1 medications that do not meet regulatory standards.The GLP-1 Saga Continues: FDA Ends the Tirzepatide ... This underscores the FDA's commitment to ensuring patient safety and the integrity of the drug supply.FDA Removes Tirzepatide Injection From Shortage List ...

For those seeking information on the availability of tirzepatide, the removal from the shortage list is a positive development. While the shortage of tirzepatide injection has been resolved, the regulatory landscape for compounded medications continues to evolve. The FDA's actions, including the issuance of declaratory orders and enforcement discretion for compounders temporarily, aim to ensure a structured transition back to normal supply channels. Patients and healthcare providers should consult with their prescribing physician and pharmacist for the most current information regarding tirzepatide availability and any specific recommendations related to compounded versus FDA-approved formulations. The FDA's constant monitoring of the drug market, including recent actions like issuing over 55 warning letters to online sellers of compounded GLP-1 versions on September 16, 2025, demonstrates an ongoing effort to regulate this space.